Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
17.01
0.00 (0.00%)
At close: Aug 24, 2026, 4:00 PM EDT
16.98
-0.03 (-0.18%)
Pre-market: Aug 25, 2026, 6:31 AM EDT
Theravance Biopharma Revenue
Theravance Biopharma had revenue of $20.73M in the quarter ending June 30, 2026, a decrease of -20.86%. This brings the company's revenue in the last twelve months to $104.31M, up 35.11% year-over-year. In the year 2025, Theravance Biopharma had annual revenue of $107.46M with 66.92% growth.
Revenue (ttm)
$104.31M
Revenue Growth
+35.11%
P/S Ratio
8.47
Revenue / Employee
$1,159,011
Employees
90
Market Cap
883.14M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 107.46M | 43.08M | 66.92% |
| Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
| Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
| Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
| Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
| Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
| Dec 31, 2019 | 73.41M | 13.04M | 21.61% |
| Dec 31, 2018 | 60.37M | 44.98M | 292.37% |
| Dec 31, 2017 | 15.39M | -33.26M | -68.37% |
| Dec 31, 2016 | 48.65M | 6.52M | 15.48% |
| Dec 31, 2015 | 42.13M | 30.44M | 260.42% |
| Dec 31, 2014 | 11.69M | 11.46M | 5,071.68% |
| Dec 31, 2013 | 226.00K | -129.92M | -99.83% |
| Dec 31, 2012 | 130.15M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Rigel Pharmaceuticals | 276.79M |
| 4D Molecular Therapeutics | 92.01M |
| Adlai Nortye | 18.06M |
| DBV Technologies | 5.04M |
| Attovia Therapeutics | 1.35M |
TBPH News
- 3 days ago - Theravance Biopharma Proxy statement: Proxy filing - Filings
- 13 days ago - Theravance Biopharma Proxy statement: Proxy filing - Filings
- 14 days ago - Theravance Biopharma reports Q2 revenue $20.7M, consensus $22.32M - TheFly
- 14 days ago - Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 14 days ago - Theravance Biopharma Earnings release: Q2 2026 - Filings
- 14 days ago - Theravance Biopharma Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 2 months ago - Zymeworks price target raised to $37 from $35 at Citi - TheFly